炎症与良性前列腺增生
Inflammation and benign prostatic hyperplasia.
作者信息
Nickel J Curtis
机构信息
Department of Urology, Queen's University, Kingston, Ontario, Canada.
出版信息
Urol Clin North Am. 2008 Feb;35(1):109-15; vii. doi: 10.1016/j.ucl.2007.09.012.
Abstract
Prostatitis, a histologic diagnosis, has evolved over the years to describe a clinical syndrome that was believed to be associated with prostatic inflammation. Similarly, benign prostatic hyperplasia (BPH), another histologic diagnosis, has evolved to describe a clinical syndrome believed to be associated with prostatic enlargement. Recent explorations of the interrelationships between these prostate-associated histologic and clinical conditions have generated much interest and excitement. This article describes these relationships and their impact on the management of, in particular, BPH.
摘要
前列腺炎，一种组织学诊断，多年来已演变为描述一种被认为与前列腺炎症相关的临床综合征。同样，良性前列腺增生（BPH），另一种组织学诊断，也已演变为描述一种被认为与前列腺肿大相关的临床综合征。最近对这些与前列腺相关的组织学和临床状况之间相互关系的探索引起了极大的兴趣和关注。本文描述了这些关系及其对特别是BPH管理的影响。
相似文献
1
Inflammation and benign prostatic hyperplasia.
Urol Clin North Am. 2008 Feb;35(1):109-15; vii. doi: 10.1016/j.ucl.2007.09.012.
2
Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: association with asymptomatic inflammatory prostatitis NIH category IV.
Scand J Urol. 2015 Apr;49(2):120-6. doi: 10.3109/21681805.2014.971427. Epub 2014 Nov 3.
3
Role of inflammation in benign prostatic hyperplasia development among Han Chinese: A population-based and single-institutional analysis.
Int J Urol. 2015 Dec;22(12):1138-42. doi: 10.1111/iju.12914. Epub 2015 Aug 27.
4
Intraepithelial lymphocytes in relation to NIH category IV prostatitis in autopsy prostate.
Prostate. 2015 Jul 1;75(10):1074-84. doi: 10.1002/pros.22991. Epub 2015 Apr 27.
5
[Further studies on the relationship between benign prostatic hyperplasia and prostatitis].
Zhonghua Nan Ke Xue. 2004 Feb;10(2):83-5.
6
Diagnostic investigations of canine prostatitis incidence together with benign prostate hyperplasia, prostate malignancies, and biochemical recurrence in high-risk prostate cancer as a model for human study.
Tumour Biol. 2015 Apr;36(4):2437-45. doi: 10.1007/s13277-014-2854-4. Epub 2014 Nov 25.
7
Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation?
Toxins (Basel). 2019 Sep 19;11(9):547. doi: 10.3390/toxins11090547.
8
The effect of prostate tissue inflammation in benign prostatic hyperplasia on enhancer of zeste homolog 2 ribonucleic acid expression.
Ann Saudi Med. 2012 May-Jun;32(3):262-8. doi: 10.5144/0256-4947.2012.262.
9
Prostatic infarction/infection in acute urinary retention secondary to benign prostatic hyperplasia.
J Urol. 1998 Sep;160(3 Pt 1):792-3. doi: 10.1016/S0022-5347(01)62788-5.
10
Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.
BJU Int. 2012 Apr;109(8):1194-7. doi: 10.1111/j.1464-410X.2011.10527.x. Epub 2011 Aug 18.
引用本文的文献
1
Integrating miRNA profiling and machine learning for improved prostate cancer diagnosis.
Sci Rep. 2025 Aug 20;15(1):30477. doi: 10.1038/s41598-025-99754-7.
2
Exploration of diagnostic biomarkers, microenvironment characteristics, and ursolic acid's therapeutic effect for benign prostate hyperplasia.
Int J Biol Sci. 2023 Aug 15;19(13):4242-4258. doi: 10.7150/ijbs.85739. eCollection 2023.
3
Mechanism of Androgen-Independent Stromal Proliferation in Benign Prostatic Hyperplasia.
Int J Mol Sci. 2023 Jul 19;24(14):11634. doi: 10.3390/ijms241411634.
4
Primary bladder neck obstruction in men-new perspectives in physiopathology.
Prostate Cancer Prostatic Dis. 2024 Mar;27(1):54-57. doi: 10.1038/s41391-023-00691-1. Epub 2023 Jul 8.
5
Increased COX-1 expression in benign prostate epithelial cells is triggered by mitochondrial dysfunction.
Am J Clin Exp Urol. 2022 Aug 15;10(4):234-245. eCollection 2022.
6
Applications of Vertebrate Models in Studying Prostatitis and Inflammation-Associated Prostatic Diseases.
Front Mol Biosci. 2022 Jul 5;9:898871. doi: 10.3389/fmolb.2022.898871. eCollection 2022.
7
Precision intervention for prostate cancer: Re-evaluating who is at risk.
Cancer Lett. 2022 Jul 10;538:215709. doi: 10.1016/j.canlet.2022.215709. Epub 2022 Apr 29.
8
High degree of prostate related LUTS in a prospective cross-sectional community study in Ghana (Mamprobi).
Heliyon. 2021 Nov 14;7(11):e08391. doi: 10.1016/j.heliyon.2021.e08391. eCollection 2021 Nov.
9
Curcumin for the Treatment of Prostate Diseases: A Systematic Review of Controlled Clinical Trials.
Adv Exp Med Biol. 2021;1291:345-362. doi: 10.1007/978-3-030-56153-6_20.
10
Heat-Killed and Live Attenuates Enlarged Prostate in an Animal Model of Benign Prostatic Hyperplasia.
J Microbiol Biotechnol. 2021 Aug 28;31(8):1134-1143. doi: 10.4014/jmb.2102.02032.
本文引用的文献
1
Longitudinal association between prostatitis and development of benign prostatic hyperplasia.
Urology. 2008 Mar;71(3):475-9; discussion 479. doi: 10.1016/j.urology.2007.11.155.
2
The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial.
Eur Urol. 2008 Dec;54(6):1379-84. doi: 10.1016/j.eururo.2007.11.026. Epub 2007 Nov 20.
3
Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial.
J Urol. 2007 Sep;178(3 Pt 1):896-900; discussion 900-1. doi: 10.1016/j.juro.2007.05.041. Epub 2007 Jul 16.
4
Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?
Eur Urol. 2007 May;51(5):1202-16. doi: 10.1016/j.eururo.2006.12.011. Epub 2006 Dec 11.
5
Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia.
Eur Urol. 2007 Feb;51(2):524-33; discussion 533. doi: 10.1016/j.eururo.2006.07.016. Epub 2006 Jul 28.
6
Definition of at-risk patients: baseline variables.
BJU Int. 2006 Apr;97 Suppl 2:7-11; discussion 21-2. doi: 10.1111/j.1464-410X.2006.06098.x.
7
Could inflammation be a key component in the progression of benign prostatic hyperplasia?
Curr Opin Urol. 2006 Jan;16(1):25-9.
8
Benign prostatic hyperplasia cell line viability and modulation of jm-27 by doxazosin and Ibuprofen.
J Urol. 2005 Jul;174(1):375-9. doi: 10.1097/01.ju.0000161598.24740.34.
9
Benign prostatic hyperplasia: age-related tissue-remodeling.
Exp Gerontol. 2005 Mar;40(3):121-8. doi: 10.1016/j.exger.2004.12.008. Epub 2005 Jan 22.
10
The healthy rat prostate contains high levels of natural killer-like cells and unique subsets of CD4+ helper-inducer T cells: implications for prostatitis.
J Urol. 2005 Mar;173(3):1004-10. doi: 10.1097/01.ju.0000149130.06055.f2.
Zotero 插件